A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

计划入组 95 人 · 首次发布于 2024 年 11 月 4 日

Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects

计划入组 71 人 · 首次发布于 2014 年 8 月 27 日

A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

计划入组 11 人 · 首次发布于 2026 年 1 月 23 日

CS-722

NGI-722

JTT-722

FameWave Ltd.

Israel

Kasetsart University

Thailand

Benmelstobart Plus Anlotinib Shows Promise in EGFR-Mutated NSCLC After TKI Failure

CheckMate 901: Nivolumab Plus Chemotherapy Improves Survival in Advanced Urothelial Carcinoma

Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC